计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Vesnarinone (60 and 100 μg/mL; 48 h) inhibits the cell growth in a dose-dependent manner. Vesnarinone (60 μg/mL; 48 h) induces G1 arrest and apoptosis. Vesnarinone (60 μg/mL; 0, 12, 24, and 48 h) treatment increases p21-mRNA expression and decreases p21 protein slightly. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL and 100 μg/mL Incubation Time: 48 hours Result: Observed more than 50% inhibition in cells treated with 100 μg/mL, and reduced 30±40% the production of MTT formazan in cells treated with 60 μg/mL. Apoptosis AnalysisCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL Incubation Time: 48 hours Result: Decreased the tumor cell population in the S phase and increased in the G1 phase. Western Blot AnalysisCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL Incubation Time: 0, 12, 24, and 48 hours Result: Increased the expression of p21-mRNA after 12±24 h vesnarinone treatment. Decreased p21 protein slightly after 24 h treatment in OSC4.
In Vivo
Vesnarinone (oral gavage; 300 mg/kg; once daily; 6 w) binds covalently to rat liver in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Lewis rats (200 g)Dosage: 300 mg/kg Administration: Oral gavage; 300 mg/kg; once daily; 6 weeks Result: Observed covalently modified liver proteins.
Form:Solid
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|